Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer

Daniel J. Turnham,Manisha S. Mullen,Nicholas P. Bullock,Kathryn L. Gilroy,Anna E. Richards,Radhika Patel,Marcos Quintela,Valerie S. Meniel,Gillian Seaton,Howard Kynaston,Richard W. E. Clarkson,Toby J. Phesse,Peter S. Nelson,Michael C. Haffner,John N. Staffurth,Helen B. Pearson

DOI: https://doi.org/10.3390/cells13080673

IF: 6

2024-04-13

Cells

Abstract:As the treatment landscape for prostate cancer gradually evolves, the frequency of treatment-induced neuroendocrine prostate cancer (NEPC) and double-negative prostate cancer (DNPC) that is deficient for androgen receptor (AR) and neuroendocrine (NE) markers has increased. These prostate cancer subtypes are typically refractory to AR-directed therapies and exhibit poor clinical outcomes. Only a small range of NEPC/DNPC models exist, limiting our molecular understanding of this disease and hindering our ability to perform preclinical trials exploring novel therapies to treat NEPC/DNPC that are urgently needed in the clinic. Here, we report the development of the CU-PC01 PDX model that represents AR-negative mCRPC with PTEN/RB/PSMA loss and CTNN1B/TP53/BRCA2 genetic variants. The CU-PC01 model lacks classic NE markers, with only focal and/or weak expression of chromogranin A, INSM1 and CD56. Collectively, these findings are most consistent with a DNPC phenotype. Ex vivo and in vivo preclinical studies revealed that CU-PC01 PDX tumours are resistant to mCRPC standard-of-care treatments enzalutamide and docetaxel, mirroring the donor patient's treatment response. Furthermore, short-term CU-PC01 tumour explant cultures indicate this model is initially sensitive to PARP inhibition with olaparib. Thus, the CU-PC01 PDX model provides a valuable opportunity to study AR-negative mCRPC biology and to discover new treatment avenues for this hard-to-treat disease.

cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop and characterize a new Patient - Derived Xenograft (PDX) model for the study of androgen receptor - negative metastatic castration - resistant prostate cancer (AR - negative mCRPC). This disease type is insensitive to the existing androgen receptor (AR) - directed therapies and has a poor clinical prognosis. Currently, the research models for this subtype of prostate cancer are very limited, which restricts the understanding of the molecular mechanisms of this disease and the conduct of pre - clinical trials of new therapies. Therefore, the main objective of the paper is to provide a PDX model that can simulate the clinical disease, in order to better study the biological characteristics of AR - negative mCRPC and explore new treatment methods.

Specifically, the CU - PC01 PDX model described in the paper has the following characteristics:
- **Genetic features**: This model carries deletions of PTEN, RB, PSMA and gene variations of CTNN1B, TP53, BRCA2.
- **Pathological features**: The CU - PC01 model lacks classic neuroendocrine markers and only shows weak Chromogranin A, INSM1 and CD56 expressions in some areas, which is in line with the phenotype of Double - Negative Prostate Cancer (DNPC).
- **Treatment response**: CU - PC01 PDX tumors are insensitive to the standard mCRPC treatment drugs Enzalutamide and Docetaxel, which is consistent with the treatment response of the donor patient. In addition, short - term CU - PC01 tumor explant cultures show that this model is initially sensitive to the PARP inhibitor Olaparib.

Through these characteristics, the CU - PC01 PDX model provides a valuable tool for studying the biological mechanisms of AR - negative mCRPC and helps to discover new treatment approaches to improve the treatment outcomes of patients with this refractory disease.